Flawed U.S. policies threaten American biopharmaceutical leadership as China accelerates clinical trials and innovation incentives.

China has tightened regulations on investigator-initiated trials, with consequences not just for Chinese researchers but some Americans, too.

Amid systemic efficiency and a wave of innovation, the country’s biotech sector is expanding at a pace that has caught the market off guard.